TD Waterhouse Canada’s Royalty Pharma RPRX Stock Holding History

TD Waterhouse Canada’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.56M	Buy	81,697 +44,764	+121%	+$2.33M	0.01%	429
2026 Q1	$1.78M	Buy	+36,933	New	+$1.62M	0.01%	580
2025 Q1	–	Sell	-13	Closed	-$331	–	2050
2024 Q4	$331	Buy	+13	New	+$345	﹤0.01%	1847

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TD Waterhouse Canada's RPRX Position: Q2 2026 in Review

TD Waterhouse Canada increased its Royalty Pharma (RPRX) stake by 121% in Q2 2026, buying an estimated $2.33M and bringing the position to 81,697 shares worth $4.56M. The position accounts for 0.01% of the portfolio, ranked #429.

TD Waterhouse Canada first reported a position in RPRX in Q4 2024 and has held it in 3 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

TD Waterhouse Canada held 81,697 shares of Royalty Pharma worth $4.56M as of Q2 2026.
TD Waterhouse Canada bought 44,764 Royalty Pharma shares in Q2 2026, an estimated $2.33M.
Royalty Pharma made up 0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #429 holding.
TD Waterhouse Canada first reported a position in Royalty Pharma in Q4 2024 and has held it in 3 quarters since.
647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.